Cargando…

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays

BACKGROUND AND AIMS: Therapeutic drug monitoring (TDM) of infliximab (IFX) and anti-infliximab antibodies (ATIs) is essential for treatment optimisation in inflammatory bowel disease (IBD) patients. The aim of this study was to estimate and compare the agreement and accuracy between a new rapid test...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Cátia, Lago, Paula, Fernandes, Samuel, Correia, Luís, Portela, Francisco, Vieira, Ana Isabel, Patita, Marta, Arroja, Bruno, Ministro, Paula, Alves, Catarina, Dias, Cláudia Camila, Magro, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682213/ https://www.ncbi.nlm.nih.gov/pubmed/33281935 http://dx.doi.org/10.1177/1756284820965790

Ejemplares similares

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Accuracy of the new rapid test for monitoring adalimumab levels
por: Rocha, Cátia, et al.
Publicado: (2019)

What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale
por: Santiago, Mafalda, et al.
Publicado: (2019)

Clinical performance of an infliximab rapid quantification assay
por: Magro, Fernando, et al.
Publicado: (2017)

Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?
por: Ministro, Paula, et al.
Publicado: (2021)

Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence
por: Santiago, Mafalda, et al.
Publicado: (2020)

Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study
por: Santiago, Mafalda, et al.
Publicado: (2020)

The risk of disabling, surgery and reoperation in Crohn’s disease – A decision tree-based approach to prognosis
por: Dias, Cláudia Camila, et al.
Publicado: (2017)

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
por: Santiago, Mafalda, et al.
Publicado: (2022)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis
por: Magro, Fernando, et al.
Publicado: (2022)

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
por: Afonso, Joana, et al.
Publicado: (2016)

Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis
por: Sousa, Paula, et al.
Publicado: (2020)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review
por: Antunes, Pedro Bernardes, et al.
Publicado: (2022)

Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
por: Magro, Fernando, et al.
Publicado: (2022)

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays
por: Afonso, Joana, et al.
Publicado: (2017)

Inflammatory bowel disease and thromboembolic events: a c’lot to learn
por: Carvalho, Ana Catarina, et al.
Publicado: (2022)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Chronic Granulomatous Disease Mimicking Colonic Crohn’s Disease Successfully Treated with Infliximab
por: Peixoto, Armando, et al.
Publicado: (2017)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

A Path Toward Inclusive Social Cohesion: The Role of European and National Identity on Contesting vs. Accepting European Migration Policies in Portugal
por: Pinto, Isabel R., et al.
Publicado: (2020)

Spitz nevus and infliximab: association or coincidence?()()
por: Queirós, Catarina Soares, et al.
Publicado: (2020)

Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
por: Beeg, Marten, et al.
Publicado: (2021)

A survey on the impact of IBD in sexual health: Into intimacy
por: Pires, Francisco, et al.
Publicado: (2022)

Novel immunoassay for TSH measurement in rats
por: Alves, Thalita G., et al.
Publicado: (2017)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

Rapid Immunoassay for the Detection of Genital Herpes Infection
por: Alexander , Samuel M., et al.
Publicado: (1994)

Comparison of rapid immunoassays for rupture of fetal membranes
por: Igbinosa, Irogue, et al.
Publicado: (2017)

Evaluation of a rapid immunoassay for bacteriuria in dogs
por: Sutter, Craig M., et al.
Publicado: (2023)

Role of a Micronized Purified Flavonoid Fraction as an Adjuvant Treatment to Rubber Band Ligation for the Treatment of Patients With Hemorrhoidal Disease: A Longitudinal Cohort Study
por: Caetano, Ana Célia, et al.
Publicado: (2019)

Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation
por: Rodrigues, Jorge, et al.
Publicado: (2023)

Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
por: Pinto-Lopes, Pedro, et al.
Publicado: (2021)

A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
por: Estevinho, Maria Manuela, et al.
Publicado: (2022)

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
por: Van Stappen, Thomas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uc94d85uer4hn1togbafid15kc